No |
Ad vector |
Transgene |
Cancer |
Phase |
Reference |
|||||||||
1 |
Ad5-SGE REIC/Dkk3 |
REIC/Dkks |
Localized Prostate cancer |
I/II |
123 |
|||||||||
2 |
Ad5-PSA |
PSA |
Prostate cancer; recurrent/hormone refractory prostate cancer |
I/II |
113, 114 |
|||||||||
3. |
Advexin (rAd-p53) |
P53 |
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx; colorectal cancer, HCC, NSCLC, prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioma, and squamous cell carcinoma of the head and neck |
I/II |
39, 108 |
|||||||||
4. |
Adv/tk (GMCI) |
HSV-tk |
Advanced non-metastatic pancreatic adenocarcinoma II |
II |
NCT02446093 |
|||||||||
5. |
Ad5-yCD/ mutTKSR39rep-hIL-12 |
Cytosine deaminase, HSV-tK, hIL-12 |
metastatic Prostate cancer |
I |
NCT03281382 |
|||||||||
6. |
Ad5-SGE REIC/Dk3 (MTG201) |
REIC/Dkk3 |
Relapsed malignant pleural mesothelioma |
II |
124 |
|||||||||
|
||||||||||||||
No |
Ad vector |
Transgene |
Cancer |
Phase |
Reference |
|||||||||
7 |
AdHSV-tk /GCV |
HSV-tk Ad- hCMV- Flt3L |
High-grade malignant gliomas |
I/II |
125 |
|||||||||
8 |
ETBX-011 |
CEA |
Metastatic colorectal cancer |
I/II |
109, 110, 126 |
|||||||||
9 |
Adv/tk |
HSV-tk |
Advanced hepatocellular carcinoma |
III |
127 |
|||||||||
10 |
SCH-58500 |
P53 |
Primary ovarian cancer, fallopian cancer and peritoneal cancer |
I |
128 |
|||||||||
11 |
ONCOS-102 |
GM-CSF |
Melanoma |
I |
64 |
|||||||||
12 |
Adv-tk (GMCI) |
Adv-tk |
Pediatric brain tumors |
I |
129 |
|||||||||
13 |
Ad-MAGEA3 |
MAGE-A3 |
Advanced/Met., MAGE-A3+ Solid Tumors, NSCLC |
I/II |
NCT02285816 |
|||||||||
14 |
rAd-IFN/Syn-3 (instiladrin) |
INFα-2b |
High grade non-muscle invasive bladder cancer |
III |
130 |
|||||||||
15 |
Ad-RTS-hIL-12 |
IL-12 |
Glioblastoma or malignant glioma; Advanced or metastatic breast cancer; recurrent or progressive melanoma |
I |
131 |
|||||||||
|
||||||||||||||
No |
Ad vector |
Transgene |
Cancer |
Phase |
Reference |
|||||||||
16 |
Ad-E6E7 and MG1-E6E7 |
HPV E6/E7 |
HPV-associated cancer |
I |
117 |
|||||||||
17 |
TILT-123 |
hTNF-α, hIL-2 |
Advanced melanoma |
I |
66 |
|||||||||
18 |
ADV/RSV-TK |
HSV-TK |
prostate cancer; glioma, retinoblastoma, mesothelioma |
I |
86-88 |
|||||||||
18 |
BG00001 |
INF-β |
Pleural melanoma |
I |
87 |
|||||||||
20 |
LOAd703 |
CD40L, 4-1BBL |
Pancreatic cancer, bacillary cancer, collateral cancer |
I/II |
NCT03225989 |
|||||||||
21 |
Adv/HSV-tk |
HSV-tk |
Metastatic non-small cell lung carcinoma and uveal melanoma |
II |
NCT02831933 |
|||||||||
22 |
DNX-2440 |
OX40L |
Glioblastoma |
I |
NCT03714334 |
|||||||||
23 |
Ad/PNP+ fludarabine |
PNP |
Head and neck squamous cell carcinoma |
1 |
132 |
|||||||||
24 |
DNX-2401 |
|
Recurrent glioma |
II |
NCT02798406 |
|||||||||
|
||||||||||||||
No |
Ad vector |
Transgene |
Cancer |
Phase |
Reference |
|||||||||
25 |
Oncorine or H101 |
|
head and neck cancer |
III |
39 |
|||||||||
26 |
Ad-MAGEA3 |
MAGE-A3 |
NSCLC |
I/II |
NCT02879760 |
|||||||||
27 |
Gendicine (rAd-p53) |
P53 |
head and neck squamous cell carcinoma, malignant glioma, HCC, NSCLC and epithelial ovarian carcinoma |
III |
133; 134 |
|||||||||
28 |
ONYX-015 |
|
Advanced cancer |
Preclinical trail |
52 |
|||||||||
29 |
ETBX-011, ETBX-061, and ETBX-051 (Tri-Ad vaccine) |
TAA |
Advanced cancer |
I |
111 |
|||||||||
30 |
ChAdOx1–MVA |
STEAP1 |
Prostate cancer |
Preclinical |
118 |
|||||||||
31 |
Ad5-yCD/ mutTKSR39rep-hIL-12 |
Cytosine deaminase, HSV-tK, IL-12 |
Prostate cancer |
I |
NCT02555397 |
|||||||||
32 |
Ad-IFN/Syn 3 |
INF-α |
Bladder cancer |
Preclinical trail |
61 |
Table 1: Clinical trials using replicating and non-replicating adenoviral vectors for cancer therapy
Tables at a glance